AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced dosing of the first patient in the Phase 1 clinical trial of A2B694. The multi-center Phase 1 dose escalation clinical trial, EVEREST-2 (NCT06051695), will evaluate safety and determine the recommended dose of A2B694 in patients with solid tumors that express mesothelin, including ovarian, mesothelioma, pancreatic, colorectal and non-small cell lung cancer, and have lost HLA-A*02 expression..

加利福尼亚州阿古拉山（商业新闻短讯）--A2 Biotherapeutics，Inc.（A2 Bio），一家开发一流的实体瘤逻辑门控细胞疗法的临床阶段细胞治疗公司，今天宣布在A2B694的1期临床试验中首次给药。多中心1期剂量递增临床试验EVEREST-2（NCT06051695）将评估安全性，并确定A2B694在表达间皮素的实体瘤患者中的推荐剂量，包括卵巢癌，间皮瘤，胰腺癌，结直肠癌和非小细胞肺癌，并已失去HLA-A*02表达。。

A2B694 is the second autologous cell therapy in clinical development by A2 Bio using its proprietary Tmod™ platform. The Tmod™ platform utilizes a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells. This dual-receptor design is intended to provide selective killing of tumor tissues that express mesothelin and have lost the HLA-A*02 gene permanently.

A2B694是A2 Bio使用其专有的Tmod™平台在临床开发中的第二种自体细胞疗法。Tmod™平台采用双受体设计，由靶向肿瘤细胞的激活剂和保护正常细胞的阻断剂组成。这种双受体设计旨在选择性杀死表达间皮素并永久丧失HLA-A*02基因的肿瘤组织。

This novel design is aimed at tackling the fundamental challenge in solid tumor cancer medicines – the ability to selectively kill tumor cells and protect normal cells..

这种新颖的设计旨在解决实体瘤癌症药物的根本挑战-选择性杀死肿瘤细胞和保护正常细胞的能力。。

“Dosing our first patient in this trial is a key step to provide a precise, novel CAR T therapy to patients with solid tumors that express mesothelin with no curative treatment options. Sadly, current treatment options for these patients are palliative and limited by toxicity in the recurrent, unresectable, locally advanced or metastatic setting.

“在这项试验中给我们的第一位患者服用药物是为表达间皮素的实体瘤患者提供精确，新颖的CAR T治疗的关键步骤，而没有治疗选择。遗憾的是，这些患者目前的治疗选择是姑息性的，并且在复发性，不可切除性，局部晚期或转移性环境中受到毒性的限制。

All of us at A2 Bio would like to thank participating patients, investigators, and clinical care providers,” said Dr. William Go, chief medical officer of A2 Bio..

A2 Bio的首席医疗官William Go博士说：“我们所有A2 Bio的人都要感谢参与的患者、研究人员和临床护理提供者。”。。

​​In addition to A2B694, A2 Bio continues to advance its clinical development of A2B530 as well as other preclinical programs as the company pursues additional pipeline expansion opportunities using its proprietary Tmod™ platform.

​​除A2B694外，A2 Bio还继续推进A2B530的临床开发以及其他临床前项目，因为该公司利用其专有的Tmod™平台寻求额外的管道扩展机会。

About EVEREST-2

关于珠穆朗玛峰-2

EVEREST-2 (NCT06051695) is a seamless Phase 1/2 study for A2B694, an autologous logic-gated investigational cell therapy developed from A2 Bio’s proprietary Tmod™ platform. The Tmod™ platform provides selective killing of tumor cells and protection of normal cells via a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells.

EVEREST-2（NCT06051695）是A2B694的无缝1/2期研究，A2B694是一种自体逻辑门控研究细胞疗法，由A2 Bio专有的Tmod™平台开发。Tmod™平台通过双受体设计提供选择性杀伤肿瘤细胞和保护正常细胞的功能，双受体设计由靶向肿瘤细胞的激活剂和保护正常细胞的阻断剂组成。

A2B694 consists of an activator that targets mesothelin (MSLN) and a blocker that targets HLA-A*02. HLA-A*02 is lost in tumor cells and present in normal cells in the eligible patient population. The study is recruiting patients with lung, colorectal, pancreatic, ovarian and mesothelioma cancers..

A2B694由靶向间皮素（MSLN）的激活剂和靶向HLA-a*02的阻断剂组成。HLA-A*02在肿瘤细胞中丢失，并存在于符合条件的患者群体的正常细胞中。该研究正在招募肺癌、结直肠癌、胰腺癌、卵巢癌和间皮瘤患者。。

About the Tmod™ Platform

关于Tmod™平台

A2 Bio has pioneered a precision-targeting cellular system – the Tmod™ mechanism – that incorporates two receptors, an activator and a blocker, to aim the powerful armaments of immune cells directly at tumors to unequivocally differentiate tumors from normal tissues. The activator recognizes antigens on tumor cells that trigger their destruction, while the blocker recognizes antigens on normal cells that protect them.

A2 Bio开创了一种精确靶向细胞系统（Tmod™机制），它结合了两种受体，一种激活剂和一种阻断剂，将强大的免疫细胞武器直接瞄准肿瘤，以明确区分肿瘤和正常组织。激活剂识别肿瘤细胞上引发其破坏的抗原，而阻断剂识别正常细胞上保护它们的抗原。

This novel blocker technology enables precise, personalized and effective T cell targeting. The blocker component equips Tmod™ cells with the capacity to identify tumors as distinct from normal cells..

这种新型阻滞剂技术可以实现精确，个性化和有效的T细胞靶向。阻滞剂成分使Tmod™细胞具有识别肿瘤与正常细胞不同的能力。。

About A2 Bio

关于A2生物

A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in cancer treatment—the ability of cancer medicines to distinguish between tumor and normal cells.

A2 Biotherapeutics，Inc.（A2 Bio）是一家临床阶段的生物技术公司，开发一流的逻辑门控细胞疗法，以解决癌症中高度未满足的需求。A2 Bio发明了专有的Tmod™细胞治疗平台，以应对癌症治疗的根本挑战-癌症药物区分肿瘤细胞和正常细胞的能力。

For more information, please visit the company’s website at www.a2bio.com..

欲了解更多信息，请访问公司网站www.a2bio.com。。